Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

This study tests a three-drug combination — iadademstat (a new oral drug), azacitidine, and venetoclax — for patients with newly diagnosed acute myeloid leukemia (AML) who are not able to tolerate standard intensive chemotherapy, often because of age or other health conditions. **You may be eligible if...** - You are 18 or older with a newly diagnosed AML (confirmed by bone marrow testing), with intermediate or high-risk genetic features - You are not a candidate for intensive chemotherapy due to age (75+) or a significant health condition such as heart problems, reduced lung function, or reduced kidney function - Patients 18–74 years old may also qualify if they have specific comorbidities that make standard chemotherapy unsafe - Your blood counts, liver function, and kidney function (creatinine clearance ≥60 mL/min) meet required levels - You are able to swallow oral medications - You agree to use contraception and provide bone marrow samples **You may NOT be eligible if...** - You have previously been treated for AML - You have a known allergy to any of the study drugs - You weigh less than 50 kg - You have an active serious infection, uncontrolled bleeding disorder, or recent stroke - You have poorly controlled diabetes (HbA1c ≥8%) or uncontrolled high blood pressure - You are pregnant or breastfeeding - You are HIV positive on certain antiretroviral treatments that interfere with study medications Talk to your doctor to see if this trial is right for you.